Clinical trials: Rituximab
Follicular Lymphoma, Marginal Zone Lymphoma
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients…
- Trial name
- SIDNEY (NCT04669171)
- Testing
- EO2463, lenalidomide, rituximab
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 80 people
- Sponsor
- Enterome
Follicular Lymphoma
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory…
- Trial name
- NCT06911502
- Testing
- Golcadomide, Rituximab, Lenalidomide
- Where
- 160 sites in United States, Australia and 19 more
- Volunteers
- 400 people
- Sponsor
- Celgene
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
This Phase Ib/II, open-label, multicenter, non-randomized study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment consisting of atezolizumab in combination with either obinutuzumab + bendamustine…
- Trial name
- NCT02596971
- Testing
- Atezolizumab, Bendamustine, Cyclophosphamide
- Where
- 21 sites in United States, Australia and 1 more
- Volunteers
- 91 people
- Sponsor
- Hoffmann-La Roche
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to establish the safety of orally administered PCI-32765 in combination with fludarabine/cyclophosphamide/rituximab (FCR) and bendamustine/rituximab (BR) in patients with chronic lymphocytic leukemia…
- Trial name
- NCT01292135
- Testing
- PCI-32765
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pharmacyclics LLC.
Diffuse Large B-cell Lymphoma (DLBCL)
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase I/II, open-label, multicenter, prospective study.
- Trial name
- NCT02957019
- Testing
- L19-IL2 - Ph I, L19-IL2 at RD - Ph II, Rituximab
- Where
- Germany
- Volunteers
- 6 people
- Sponsor
- Philogen S.p.A.
Lupus Erythematosus, Systemic
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus
This is a Phase II/III open label, single-arm, multicenter, extension study to evaluate the safety and efficacy of rituximab when administered on a scheduled basis every 6 months over the course of 1 year with reassessment of…
- Trial name
- VOYAGER (NCT00381810)
- Testing
- Rituximab, Methylprednisolone, Acetaminophen
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20).
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
- Trial name
- EPCORE™ CLL-1 (NCT04623541)
- Testing
- Epcoritamab, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, Venetoclax
- Where
- 81 sites in United States, Australia and 10 more
- Volunteers
- 194 people
- Sponsor
- Genmab
Non-Hodgkin's Lymphoma
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
The purpose of this research study is to find out if treatment with rituximab in combination with aldesleukin (compared to rituximab alone) decreases the risk of cancer returning, as well as determining what other effects (good…
- Trial name
- NCT00250861
- Testing
- Rituximab, Aldesleukin
- Where
- 21 sites in United States
- Volunteers
- 110 people
- Sponsor
- US Oncology Research
Chronic Lymphocytic Leukemia
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in…
- Trial name
- AMPLIFY (NCT03836261)
- Testing
- Acalabrutinib, Venetoclax, Chemoimmunotherapy
- Where
- 169 sites in United States, Argentina and 25 more
- Volunteers
- 984 people
- Sponsor
- Acerta Pharma BV
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma.
- Trial name
- NCT01998893
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 11 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
CLL
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
- Trial name
- CORAL (NCT05209308)
- Testing
- Zandelisib, Rituximab, Venetoclax
- Where
- 4 sites in United States
- Sponsor
- MEI Pharma, Inc.
Rheumatoid Arthritis
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate
This 2 part study will investigate the safety, tolerability and efficacy of MabT hera in combination with RoActemra in patients with active rheumatoid arthritis despite a stable dose of methotrexate.
- Trial name
- NCT00845832
- Testing
- rituximab [MabThera/Rituxan], tocilizumab [RoActemra/Actemra]
- Where
- 24 sites in France, Germany and 6 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Non-Hodgkin's Lymphoma
GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma.
- Trial name
- NCT00576758
- Testing
- obinutuzumab (RO5072759), rituximab
- Where
- 71 sites in United States, Argentina and 15 more
- Volunteers
- 175 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B-cell Lymphoma
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
The Purpose of This Study is to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics between TQB2303 and Rituximab in Combination With CHOP in Previously Untreated Patients with Diffuse Large B-cell Lymphoma
- Trial name
- NCT03777085
- Testing
- TQB2303, Rituximab
- Where
- 31 sites in China
- Volunteers
- 230 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Diffuse Large B-Cell Lymphoma
An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
- Trial name
- NCT01340443
- Where
- 24 sites in China
- Volunteers
- 314 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
An Observational Study of Rituximab in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis
This observational study will assess the efficacy and safety of combination of rituximab (MabThera) and methotrexate in participants with active refractory rheumatoid arthritis (RA) who have failed to respond to a single course…
- Trial name
- NCT01283399
- Where
- 5 sites in Lebanon
- Volunteers
- 79 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia
This study will examine the effectiveness of MabThera therapy added to a standard chemotherapy regimen for the treatment of previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT02080884
- Where
- 15 sites in Hungary
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Large B-Cell, Diffuse
To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL
Part 1 (Phase Ib) Primary objective: To establish the maximum tolerated dose (MTD) of BI 836826 in combination with GemOx. Secondary objectives: To evaluate pharmacokinetics of BI 836826 when given in combination with GemOx and…
- Trial name
- NCT02624492
- Testing
- BI 836826, GemOx, Rituximab
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone…
- Trial name
- NCT00877006
- Testing
- bendamustine, rituximab, vincristine
- Where
- 128 sites in United States, Australia and 5 more
- Volunteers
- 447 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.